Medical Technology Assessment Board should fix prices of stents: Nathealth

Nathealth represents entire spectrum of healthcare professionals including hospitals, manufacturers

As the fight between multinational stent providers and domestic manufacturers intensifies over stent pricing, the healthcare federation of India Nathealth has proposed that the Medical Technology Assessment Board should be fixing prices based on the efficacy of the stents.

Anjan Bose from the federation told Business Standard, “Let Medical Technology Assessment Board examine stents and set prices based on their efficacy.”

In a recent meeting held by the National Pharmaceutical Pricing Authority (NPPA) with stakeholders, Nathealth had also supported the request of multi-national stent manufacturers that there should be differential pricing.

Nathealth is a body that represents the entire spectrum